In last trading session, Day One Biopharmaceuticals Inc (NASDAQ:DAWN) saw 1.51 million shares changing hands with its beta currently measuring -1.45. Company’s recent per share price level of $17.69 trading at $0.59 or 3.45% at ring of the bell on the day assigns it a market valuation of $1.55B. That closing price of DAWN’s stock is at a discount of -0.9% from its 52-week high price of $17.85 and is indicating a premium of 45.34% from its 52-week low price of $9.67. Taking a look at company’s average trading volume volume of 1.00 million if we extend that period to 3-months.
Day One Biopharmaceuticals Inc (NASDAQ:DAWN) trade information
Upright in the green during last session for gaining 3.45%, in the last five days DAWN remained trading in the green while hitting it’s week-highest on Wednesday, 05/01/24 when the stock touched $17.69 price level, adding 2.1% to its value on the day. Day One Biopharmaceuticals Inc’s shares saw a change of 21.16% in year-to-date performance and have moved 16.46% in past 5-day. Day One Biopharmaceuticals Inc (NASDAQ:DAWN) showed a performance of 11.68% in past 30-days.
Day One Biopharmaceuticals Inc (DAWN) estimates and forecasts
Statistics highlight that Day One Biopharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 48.66% of value to its shares in past 6 months, showing an annual growth rate of -12.66% while that of industry is 12.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -11.90% in the current quarter and calculating -9.80% decrease in the next quarter.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of -$ for the same. And 8 analysts are in estimates of company making revenue of $890k in the next quarter that will end on Jun 2024. Company posted -$ and -$ of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -84.59% during past 5 years.
DAWN Dividends
Day One Biopharmaceuticals Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
